BTIG Maintains Buy on Guardant Health, Raises Price Target to $190
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ: GH ) with a Buy and raises the price target from $160 to $190.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.